CN118490817A - 狂犬病毒疫苗 - Google Patents

狂犬病毒疫苗 Download PDF

Info

Publication number
CN118490817A
CN118490817A CN202410181783.1A CN202410181783A CN118490817A CN 118490817 A CN118490817 A CN 118490817A CN 202410181783 A CN202410181783 A CN 202410181783A CN 118490817 A CN118490817 A CN 118490817A
Authority
CN
China
Prior art keywords
rabies virus
vaccine
rna replicon
antigen
alphavirus rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410181783.1A
Other languages
English (en)
Chinese (zh)
Inventor
I·塔佩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of CN118490817A publication Critical patent/CN118490817A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202410181783.1A 2017-11-06 2018-11-05 狂犬病毒疫苗 Pending CN118490817A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762581955P 2017-11-06 2017-11-06
US62/581,955 2017-11-06
PCT/EP2018/080086 WO2019086645A1 (en) 2017-11-06 2018-11-05 Rabies virus vaccine
CN201880071826.3A CN111315409A (zh) 2017-11-06 2018-11-05 狂犬病毒疫苗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880071826.3A Division CN111315409A (zh) 2017-11-06 2018-11-05 狂犬病毒疫苗

Publications (1)

Publication Number Publication Date
CN118490817A true CN118490817A (zh) 2024-08-16

Family

ID=64316485

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410181783.1A Pending CN118490817A (zh) 2017-11-06 2018-11-05 狂犬病毒疫苗
CN201880071826.3A Pending CN111315409A (zh) 2017-11-06 2018-11-05 狂犬病毒疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880071826.3A Pending CN111315409A (zh) 2017-11-06 2018-11-05 狂犬病毒疫苗

Country Status (8)

Country Link
US (1) US11992526B2 (https=)
EP (1) EP3706791A1 (https=)
JP (3) JP7472019B2 (https=)
CN (2) CN118490817A (https=)
AU (2) AU2018360288B2 (https=)
BR (1) BR112020008240A2 (https=)
CA (1) CA3080425A1 (https=)
WO (1) WO2019086645A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11167027B2 (en) 2017-11-06 2021-11-09 Intervet Inc. Multivalent feline vaccine
US20230355741A1 (en) 2020-05-11 2023-11-09 Intervet Inc. Feline Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
MX2023005495A (es) 2020-11-12 2023-05-23 Intervet Int Bv Vectores recombinantes que codifican para proteinas espiculares quimericas del coronavirus y uso de los mismos.
US11730804B1 (en) * 2022-04-13 2023-08-22 Replicate Bioscience, Inc. Compositions and methods for the prevention and treatment of rabies virus infection
CN119552227B (zh) * 2023-12-15 2025-09-12 烟台派诺生物技术有限公司 狂犬病病毒g蛋白突变体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208161B1 (en) * 1997-05-23 2007-04-24 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
CN1989250B (zh) 2004-05-18 2013-11-20 阿尔法瓦克斯公司 Tc-83衍生的甲病毒属载体、颗粒和方法
CA2626253A1 (en) * 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
US8460913B2 (en) 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
KR101847908B1 (ko) 2010-11-05 2018-04-11 노바백스, 인코포레이티드 광견병 당단백질 바이러스-유사 입자(VLPs)
RU2014118727A (ru) * 2011-10-11 2015-11-20 Новартис Аг Рекомбинантные самореплицирующиеся полицистронные молекулы рнк
WO2013138776A1 (en) * 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
BR112016001192A2 (pt) * 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva

Also Published As

Publication number Publication date
JP2021501757A (ja) 2021-01-21
AU2018360288B2 (en) 2025-05-22
JP7714009B2 (ja) 2025-07-28
AU2018360288A1 (en) 2020-05-07
WO2019086645A1 (en) 2019-05-09
CA3080425A1 (en) 2019-05-09
AU2025220796A1 (en) 2025-09-11
RU2020117697A3 (https=) 2022-03-03
CN111315409A (zh) 2020-06-19
JP2024001076A (ja) 2024-01-09
BR112020008240A2 (pt) 2020-11-17
RU2020117697A (ru) 2021-12-08
US11992526B2 (en) 2024-05-28
JP7472019B2 (ja) 2024-04-22
JP2025169249A (ja) 2025-11-12
US20200345832A1 (en) 2020-11-05
EP3706791A1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
JP7714009B2 (ja) 狂犬病ウイルスワクチン
JP7731670B2 (ja) ネコ白血病ウイルスワクチン
JP7721604B2 (ja) ネコカリシウイルスワクチン
US20240398934A1 (en) Feline leukemia virus vaccine
JP7427585B2 (ja) 多価ネコワクチン
US11229699B2 (en) Feline calicivirus vaccine
RU2782350C2 (ru) Вакцина против вируса бешенства
US20240269259A1 (en) Rabies virus vaccine
BR122025024306A2 (pt) Composição imunogênica, uso da mesma e vacina para auxiliar na prevenção de doença devido ao vírus da raiva

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination